Literature DB >> 2018366

Increased toxicity and DNA cross-linking by peptide bound m-L-sarcolysin (Peptichemio) as compared to melphalan and m-L-sarcolysin in human melanoma cell lines.

R Lewensohn1, H Ehrsson, J Hansson, U Ringborg.   

Abstract

Alteration of the melphalan molecule by shifting the di(2-choroethyl)aminogroup from the para- to the meta-position of the phenylalanine residue results in m-L-sarcolysin. By covalent conjugation of different amino acids at the amino- and carboxylgroups of this molecule, a mixture of six peptides known as Peptichemio has been synthesized. In a previous investigation we found that Peptichemio was less toxic to human lymphoblasts than m-L-sarcolysin. In contrast, in the present investigation we found that Peptichemio has higher cytotoxic effect than m-L-sarcolysin on two human melanoma cell lines. The higher cytotoxicity was paralleled by a higher induction of DNA cross-links by Peptichemio as compared to m-L-sarcolysin. A comparative analysis of the six peptides on Peptichemio showed differences in cytotoxic effects on a melanoma cell line. One of the six peptides displayed a considerably higher cytotoxicity than peptichemio itself.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2018366

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  4 in total

1.  Efficacy of peptide bound m-L-sarcolysin (peptichemio) on melphalan resistant human myeloma cells in vitro.

Authors:  R Lewensohn; J O Fernberg; H Ehrsson; G Merlini
Journal:  Med Oncol Tumor Pharmacother       Date:  1991

2.  Pharmacokinetics of peptichemio in myeloma patients: release of m-L-sarcolysin in vivo and in vitro.

Authors:  H Ehrsson; R Lewensohn; I Wallin; M Hellström; G Merlini; B Johansson
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

3.  Comparison of the cytotoxic activity of melphalan with L-prolyl-m-L-sarcolysyl-L-p-fluorophenylalanine in human tumour cell lines and primary cultures of tumour cells from patients.

Authors:  R Larsson; S Dhar; H Ehrsson; P Nygren; R Lewensohn
Journal:  Br J Cancer       Date:  1998-08       Impact factor: 7.640

Review 4.  Spotlight on Melphalan Flufenamide: An Up-and-Coming Therapy for the Treatment of Myeloma.

Authors:  Fortunato Morabito; Giovanni Tripepi; Enrica Antonia Martino; Ernesto Vigna; Francesco Mendicino; Lucio Morabito; Katia Todoerti; Hamdi Al-Janazreh; Graziella D'Arrigo; Filippo Antonio Canale; Giovanna Cutrona; Antonino Neri; Massimo Martino; Massimo Gentile
Journal:  Drug Des Devel Ther       Date:  2021-07-08       Impact factor: 4.162

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.